Publicacións en colaboración con investigadores/as de Gustave Roussy Cancer Campus (35)

2024

  1. Comprehensive analysis of constitutional mismatch repair deficiency-associated non-Hodgkin lymphomas in a global cohort

    Pediatric Blood and Cancer

2023

  1. Fibroblasts generate topographical cues that steer cancer cell migration

    Science advances, Vol. 9, Núm. 33, pp. eade2120

2022

  1. Breast cancer risks associated with missense variants in breast cancer susceptibility genes

    Genome Medicine, Vol. 14, Núm. 1

  2. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

    The Lancet Oncology, Vol. 23, Núm. 3, pp. 362-373

  3. Tackling Thyroid Cancer in Europe—The Challenges and Opportunities

    Healthcare (Switzerland), Vol. 10, Núm. 9

2021

  1. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

    Nature Communications, Vol. 12, Núm. 1

  2. Glossary on atmospheric electricity and its effects on biology

    International Journal of Biometeorology, Vol. 65, Núm. 1, pp. 5-29

  3. Immunotherapy-induced isolated ACTH deficiency in cancer therapy

    Endocrine-related cancer, Vol. 28, Núm. 12, pp. 783-792

  4. Report of the fifth meeting of the European Consortium 'Care for CMMRD' (C4CMMRD), Leiden, The Netherlands, July 6th 2019

    Familial Cancer, Vol. 20, Núm. 1, pp. 67-73

  5. The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

    Genetics in Medicine, Vol. 23, Núm. 9, pp. 1726-1737

2020

  1. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    The Lancet Oncology, Vol. 21, Núm. 12, pp. 1574-1588

  2. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

    Nature Genetics, Vol. 52, Núm. 1, pp. 56-73

2019

  1. EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer

    European Journal of Cancer, Vol. 117, pp. 60-68

  2. Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients

    Clinical Lung Cancer, Vol. 20, Núm. 4, pp. 305-312.e3

  3. Novel common genetic susceptibility loci for colorectal cancer

    Journal of the National Cancer Institute, Vol. 111, Núm. 2, pp. 146-157

  4. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

    npj Breast Cancer, Vol. 5, Núm. 1

2018

  1. BRCA1 and BRCA2 5′ noncoding region variants identified in breast cancer patients alter promoter activity and protein binding

    Human Mutation, Vol. 39, Núm. 12, pp. 2025-2039

  2. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: A Meta-analysis

    Journal of the National Cancer Institute, Vol. 110, Núm. 6, pp. 560-567

  3. Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer

    Oncotarget, Vol. 9, Núm. 25, pp. 17334-17348

2017

  1. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

    Nature Genetics, Vol. 49, Núm. 5, pp. 680-691